Cutting Edge Molecular Therapy for Acute Myeloid Leukemia

被引:7
作者
Miyamoto, Kenichi [1 ]
Minami, Yosuke [1 ]
机构
[1] Natl Canc Ctr Hosp East, Dept Hematol, Kashiwa, Chiba 2778577, Japan
关键词
acute myeloid leukemia; FMS-like tyrosine kinase 3; isocitrate dehydrogenase; immune checkpoint inhibitor; chimeric antigen receptor; CONVENTIONAL CARE REGIMENS; PHASE-II TRIAL; TERM-FOLLOW-UP; T-CELL; COMPLEX KARYOTYPE; NEDD8-ACTIVATING ENZYME; CYTOSINE-ARABINOSIDE; OLDER PATIENTS; ADULT PATIENTS; MUTANT LEVEL;
D O I
10.3390/ijms21145114
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently, whole exome sequencing for acute myeloid leukemia (AML) has been performed by a next-generation sequencer in several studies. It has been revealed that a few gene mutations are identified per AML patient. Some of these mutations are actionable mutations that affect the response to an approved targeted treatment that is available for off-label treatment or that is available in clinical trials. The era of precision medicine for AML has arrived, and it is extremely important to detect actionable mutations relevant to treatment decision-making. However, the percentage of actionable mutations found in AML is about 50% at present, and therapeutic development is also needed for AML patients without actionable mutations. In contrast, the newly approved drugs are less toxic than conventional intensive chemotherapy and can be combined with low-intensity treatments. These combination therapies can contribute to the improvement of prognosis, especially in elderly AML patients who account for more than half of all AML patients. Thus, the treatment strategy for leukemia is changing drastically and showing rapid progress. In this review, we present the latest information regarding the recent development of treatment for AML.
引用
收藏
页码:1 / 23
页数:23
相关论文
共 125 条
[41]   Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia [J].
Feng, Zizhen ;
Yao, Yuan ;
Zhou, Chao ;
Chen, Fengju ;
Wu, Fangrui ;
Wei, Liping ;
Liu, Wei ;
Dong, Shuo ;
Redell, Michele ;
Mo, Qianxing ;
Song, Yongcheng .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
[42]  
Finn LE, 2017, BLOOD, V130
[43]   Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation [J].
Freeman, GJ ;
Long, AJ ;
Iwai, Y ;
Bourque, K ;
Chernova, T ;
Nishimura, H ;
Fitz, LJ ;
Malenkovich, N ;
Okazaki, T ;
Byrne, MC ;
Horton, HF ;
Fouser, L ;
Carter, L ;
Ling, V ;
Bowman, MR ;
Carreno, BM ;
Collins, M ;
Wood, CR ;
Honjo, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) :1027-1034
[44]   Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia [J].
Friedrich, Matthias ;
Henn, Anja ;
Raum, Tobias ;
Bajtus, Monika ;
Matthes, Katja ;
Hendrich, Larissa ;
Wahl, Joachim ;
Hoffmann, Patrick ;
Kischel, Roman ;
Kvesic, Majk ;
Slootstra, Jerry W. ;
Baeuerle, Patrick A. ;
Kufer, Peter ;
Rattel, Benno .
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (06) :1549-1557
[45]   The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia [J].
Gale, Rosemary E. ;
Green, Claire ;
Allen, Christopher ;
Mead, Adam J. ;
Burnett, Alan K. ;
Hils, Robert K. ;
Linch, David C. .
BLOOD, 2008, 111 (05) :2776-2784
[46]   Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia [J].
Goellner, Stefanie ;
Oellerich, Thomas ;
Agrawal-Singh, Shuchi ;
Schenk, Tino ;
Klein, Hans-Ulrich ;
Rohde, Christian ;
Pabst, Caroline ;
Sauer, Tim ;
Lerdrup, Mads ;
Tavor, Sigal ;
Stoelzel, Friedrich ;
Herold, Sylvia ;
Ehninger, Gerhard ;
Koehler, Gabriele ;
Pan, Kuan-Ting ;
Urlaub, Henning ;
Serve, Hubert ;
Dugas, Martin ;
Spiekermann, Karsten ;
Vick, Binje ;
Jeremias, Irmela ;
Berdel, Wolfgang E. ;
Hansen, Klaus ;
Zelent, Arthur ;
Wickenhauser, Claudia ;
Mueller, Lutz P. ;
Thiede, Christian ;
Mueller-Tidow, Carsten .
NATURE MEDICINE, 2017, 23 (01) :69-78
[47]   FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance [J].
Grunwald, Michael R. ;
Levis, Mark J. .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (06) :683-694
[48]   The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells [J].
Harris, William J. ;
Huang, Xu ;
Lynch, James T. ;
Spencer, Gary J. ;
Hitchin, James R. ;
Li, Yaoyong ;
Ciceri, Filippo ;
Blaser, Julian G. ;
Greystoke, Brigit F. ;
Jordan, Allan M. ;
Miller, Crispin J. ;
Ogilvie, Donald J. ;
Somervaille, Tim C. P. .
CANCER CELL, 2012, 21 (04) :473-487
[49]   Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells [J].
Hauswirth, A. W. ;
Florian, S. ;
Printz, D. ;
Sotlar, K. ;
Krauth, M. -T. ;
Fritsch, G. ;
Schernthaner, G. -H. ;
Wacheck, V. ;
Selzer, E. ;
Sperr, W. R. ;
Valent, P. .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 (01) :73-82
[50]   A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia [J].
He, Simon Z. ;
Busfield, Samantha ;
Ritchie, David S. ;
Hertzberg, Mark S. ;
Durrant, Simon ;
Lewis, Ian D. ;
Marlton, Paula ;
McLachlan, Andrew J. ;
Kerridge, Ian ;
Bradstock, Kenneth F. ;
Kennedy, Glen ;
Boyd, Andrew W. ;
Yeadon, Trina M. ;
Lopez, Angel F. ;
Ramshaw, Hayley S. ;
Iland, Harry ;
Bamford, Simone ;
Barnden, Megan ;
DeWitte, Mark ;
Basser, Russell ;
Roberts, Andrew W. .
LEUKEMIA & LYMPHOMA, 2015, 56 (05) :1406-1415